GlobalData on MSN1 个月
Are dry powder inhalers the key to sustainable respiratory care?
AstraZeneca’s Symbicort inhaler accounts for most of its inhalation portfolio revenue, projected by GlobalData to generate a total $2.5bn in 2024. Meanwhile GSK's lead inhalers include Trelegy Ellipta ...